214 related articles for article (PubMed ID: 19609462)
1. Genetic and epigenetic regulations of prostate cancer by genistein.
Molinié B; Georgel P
Drug News Perspect; 2009 Jun; 22(5):247-54. PubMed ID: 19609462
[TBL] [Abstract][Full Text] [Related]
2. Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress.
Raschke M; Rowland IR; Magee PJ; Pool-Zobel BL
Carcinogenesis; 2006 Nov; 27(11):2322-30. PubMed ID: 16774941
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
4. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification.
Majid S; Kikuno N; Nelles J; Noonan E; Tanaka Y; Kawamoto K; Hirata H; Li LC; Zhao H; Okino ST; Place RF; Pookot D; Dahiya R
Cancer Res; 2008 Apr; 68(8):2736-44. PubMed ID: 18413741
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide DNA methylation modified by soy phytoestrogens: role for epigenetic therapeutics in prostate cancer?
Karsli-Ceppioglu S; Ngollo M; Adjakly M; Dagdemir A; Judes G; Lebert A; Boiteux JP; Penault-LLorca F; Bignon YJ; Guy L; Bernard-Gallon D
OMICS; 2015 Apr; 19(4):209-19. PubMed ID: 25831061
[TBL] [Abstract][Full Text] [Related]
6. Use of cross species genomic profiling identifies pathways and genes differentially regulated in prostate cancer cells treated with soy protein isolates or purified genistein.
Liss MA; Schlicht M; Degueme A; Hessner M; Datta MW
Cancer Genomics Proteomics; 2010; 7(3):111-28. PubMed ID: 20551244
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic mechanisms in the biology of prostate cancer.
Schulz WA; Hoffmann MJ
Semin Cancer Biol; 2009 Jun; 19(3):172-80. PubMed ID: 19429481
[TBL] [Abstract][Full Text] [Related]
8. Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines.
Rabiau N; Kossaï M; Braud M; Chalabi N; Satih S; Bignon YJ; Bernard-Gallon DJ
Cancer Epidemiol; 2010 Apr; 34(2):200-6. PubMed ID: 20097631
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
10. Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
Skogseth H; Follestad T; Larsson E; Halgunset J
APMIS; 2006 May; 114(5):364-71. PubMed ID: 16725013
[TBL] [Abstract][Full Text] [Related]
11. Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer.
Bilir B; Sharma NV; Lee J; Hammarstrom B; Svindland A; Kucuk O; Moreno CS
Int J Oncol; 2017 Jul; 51(1):223-234. PubMed ID: 28560383
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic biomarkers for human cancer: the time is now.
Mulero-Navarro S; Esteller M
Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic opportunities and challenges in cancer.
Best JD; Carey N
Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
15. Soy, isoflavones, and prostate cancer.
Jian L
Mol Nutr Food Res; 2009 Feb; 53(2):217-26. PubMed ID: 18985655
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Privat M; Aubel C; Arnould S; Communal Y; Ferrara M; Bignon YJ
Biochem Biophys Res Commun; 2009 Feb; 379(3):785-9. PubMed ID: 19126406
[TBL] [Abstract][Full Text] [Related]
17. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies.
Taylor CK; Levy RM; Elliott JC; Burnett BP
Nutr Rev; 2009 Jul; 67(7):398-415. PubMed ID: 19566600
[TBL] [Abstract][Full Text] [Related]
18. Soy isoflavone genistein in prevention and treatment of prostate cancer.
Perabo FG; Von Löw EC; Ellinger J; von Rücker A; Müller SC; Bastian PJ
Prostate Cancer Prostatic Dis; 2008; 11(1):6-12. PubMed ID: 17923857
[TBL] [Abstract][Full Text] [Related]
19. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
20. The application of epigenetic modifiers on the treatment of prostate and bladder cancer.
Zhang Z; Karam J; Frenkel E; Sagalowsky A; Hsieh JT
Urol Oncol; 2006; 24(2):152-60. PubMed ID: 16520279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
